Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Sleep disturbance and recurring headaches can negatively affect daily functioning, mood, and productivity. MyVitalC (ESS60 in extra virgin olive oil) is a commercially available dietary supplement that has generated anecdotal claims related to sleep quality and headache relief; however, human data remain limited.
This real-world observational study is designed to help participants evaluate whether use of MyVitalC is associated with changes in sleep disturbance and headache frequency or severity in their own daily lives. Participants will complete a four-week baseline observation period without the intervention, followed by six weeks of daily MyVitalC use, with weekly self-reported assessments. Participants serve as their own control, allowing for within-person comparison of outcomes before and during product use.
This single-arm observational study uses a structured baseline-plus-intervention design to assess within-participant changes in sleep disturbance and everyday headache outcomes associated with MyVitalC use.
Participants first complete a four-week baseline period during which no study intervention is taken. During this time, participants complete weekly assessments to characterize their typical sleep disturbance and headache patterns. Following baseline, participants begin daily use of MyVitalC for six weeks and continue completing weekly assessments.
The study employs validated patient-reported outcome measures, including the PROMIS Sleep Disturbance Scale and PROMIS Pain Interference Scale, as well as a custom Weekly Headache Check-In. Data will be used to generate individual-level comparisons between baseline and during-use periods. The study is designed as a signal-detection and personal-outcome evaluation trial rather than a randomized controlled efficacy study.
More information can be found at the study recruitment landing page: https://app.efforia.com/myvitalc-sleep-migraine-management/
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Arm longitudinal where participants act as their own control | Experimental | Single Arm longitudinal where participants act as their own control |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MyVitalC (ESS60 in Extra Virgin Olive Oil) | Dietary Supplement | Participants will take 1 teaspoon (5 mL) of MyVitalC, ESS60 in extra virgin olive oil, orally once daily in the morning, with or without food, for six weeks. Daily intake is logged within the study platform. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Sleep Disturbance | Measure: PROMIS Sleep Disturbance Scale Description: Assesses perceived sleep quality, sleep depth, and sleep-related difficulties. Higher scores indicate greater sleep disturbance. | Weekly during baseline (4 weeks) and weekly during intervention (6 weeks) |
| Change in Headache Frequency | Measure: Weekly Headache Check-In (frequency count) Description: Number of headaches experienced in the past 7 days. | Weekly during baseline and intervention, and on day 70 (end of study) |
| Change in Headache Severity | Measure: Weekly Headache Check-In (severity rating) Description: Participant-reported severity of the worst headache experienced during the past 7 days. | Weekly during baseline and intervention, and on day 70 (end of study) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Pain Interference | Measure: PROMIS Pain Interference Scale Description: Assesses the extent to which pain interferes with daily activities and functioning. | Baseline and day 70 (end of study) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Matthew Amsden | Contact | (646) 679-2479 | help@efforia.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Efforia | Recruiting | New York | New York | 10003 | United States |
Not provided
| Label | URL |
|---|---|
| Study Recruitment Landing Page | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D006261 | Headache |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Participants serve as their own control using an extended baseline observation period followed by an intervention period. Outcomes during MyVitalC use are compared against each participant's own baseline averages.
Not provided
Not provided
Not provided
Not provided